October 16, 2013Annals of Pharmacotherapy

Assessment of Bleeding Events Associated With Short-Duration Therapeutic Enoxaparin Use in the Morbidly Obese

View Full Paper

Ask AI

Bookmark

Why the study?

Does therapeutic enoxaparin dosing in morbidly obese patients increase bleeding events compared to lower-weight patients?

Population

Patients at a single academic medical center receiving enoxaparin for at least 24 hours, including morbidly…

Comparison

Therapeutic enoxaparin in morbidly obese patients. vs Therapeutic enoxaparin in lower-weight matched…

Design

Cohort

Follow-up

Up to 24 hours after enoxaparin administration

Authors

JHJ. HagopianUniversity of Michigan JRJennifer N. RineyMissouri Baptist Medical Center JHJames M. HollandsCooper University Health Care

Discussion

Member takes

Implication

Capped enoxaparin dosing was not associated with excess bleeding in morbidly obese patients; leaves open need for randomized confirmation.

Structured PICO

Does therapeutic enoxaparin dosing in morbidly obese patients increase bleeding events compared to lower-weight patients?

Population

Patients at a single academic medical center receiving enoxaparin for at least 24 hours, including morbidly obese patients (BMI ≥ 40 kg/m²) matched 1:2 with lower-weight controls based on renal dysfunction (serum creatinine >1.4 mg/dL).

Intervention

Therapeutic enoxaparin in morbidly obese patients (mean dose 0.98 mg/kg, capped at 150 mg).

Comparator

Therapeutic enoxaparin in lower-weight matched controls (mean dose 1.04 mg/kg).

Outcome

Bleeding events (defined by laboratory changes, administration of blood products, or clinical data) occurring up to 24 hours after enoxaparin administration.safety

Dosing therapeutic enoxaparin in morbidly obese patients (up to 175 kg) with doses capped at 150 mg was not associated with a significant increase in bleeding incidence compared to lower-weight patients.

Cite This Study

Hagopian et al. (2013) studied this question.

synapsesocial.com/papers/6a728f9da7fbea1e4408b16c https://doi.org/10.1177/1060028013506404

View Full Paper

Ask AI

Bookmark

Implication

Capped enoxaparin dosing was not associated with excess bleeding in morbidly obese patients; leaves open need for randomized confirmation.

Assessment of Bleeding Events Associated With Short-Duration Therapeutic Enoxaparin Use in the Morbidly Obese

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Assessment of Bleeding Events Associated With Short-Duration Therapeutic Enoxaparin Use in the Morbidly Obese

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider